PeproMene Bio Raised $31 million in a Series B Funding
Irvine, CA, May 16, 2018 – Today, PeproMene Bio, Inc. announced that the Company closed its Series B funding process on May 15, 2017, and had raised $31 million in a Series B funding from KOSDAQ listed companies, private companies, and various public & private funds. The primary use of this will fund the Company’s research in pre-clinical program, devemopment in further clinical trial, and for general corporate purposes. The company totally raised $40 million from the seed funding to this Series B funding.
About PeproMene Bio
PeproMene Bio, Inc. is a virtual, privately funded biotech company located Irvine, CA. We are developing novel immune-oncology therapies such as BAFF-R CAR-T therapy based on the novel antibodies. The BAFF-R CAR-T therapy program which was discovered and developed from Dr. Larry Kwak’s lab at MD Anderson and City of Hope was successfully licensed in from City of Hope, Duarte CA, in April 2017. Currently the further development is ongoing at City of Hope for its IND enabling study. We will continue to license-in and explore more of novel immuno-oncology programs via our network. For more information about the Company, please visit www.pepromenebio.com.
Steve Lee: 949-564-4085, firstname.lastname@example.org